Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection

Area of Science:

• Gastroenterology
• Microbiology
• Immunology

Background:

• Recurrent Clostridioides difficile infection (CDI) poses a significant challenge for patients with inflammatory bowel disease (IBD).
• Fecal microbiota transplantation (FMT) is an emerging therapy for recurrent CDI.
• Prospective data on FMT's impact on IBD activity are limited, despite anecdotal concerns.

Purpose of the Study:

• To evaluate the safety and efficacy of FMT in IBD patients experiencing recurrent CDI.
• To assess the impact of FMT on IBD activity, including flares and improvement.
• To analyze microbiome and metabolomic changes post-FMT in this patient population.

Main Methods:

• Secondary analysis of an open-label, prospective, multicenter cohort study.
• Participants with IBD and at least two CDI episodes received a single FMT via colonoscopy.
• IBD activity was assessed using Mayo or Harvey-Bradshaw index scores; microbiome and metabolomic profiling were performed.

Main Results:

• Among 49 treated patients, 73.3% with Crohn's disease and 62% with ulcerative colitis showed IBD improvement.
• A small percentage of ulcerative colitis patients experienced a de novo flare (4%).
• FMT increased gut microbial alpha diversity, with ulcerative colitis patients showing greater similarity to the donor microbiome post-treatment.

Conclusions:

• FMT appears to be a promising therapeutic option for IBD patients with recurrent CDI.
• The outcomes observed in this prospective trial suggest FMT may be more beneficial than previously indicated by retrospective studies.
• FMT demonstrates a favorable safety profile and potential for improving IBD activity in this complex patient group.